Citius Pharmaceuticals price to book ratio CTXR

Market value divided by the book value of the company's net assets, since 2016.

Today, Oct 23, 2026: 0.2×
10-year median: 32.5×
Against its 10-year history: 2nd; percentile: 0 is its lowest day, 100 its highest
10-year range: 0.1× to 164×
Peer median: 1.6×

Citius Pharmaceuticals' price to book ratio is 0.2× as of Oct 23, 2026.

That is below its ten-year median of 32.5×, lower than on 98% of days in the last ten years.

Over that time it ranged from 0.1× in May 2025 to 164× in Apr 2021.

The median for 3 large drugmakers of a similar size is 1.6×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	0.2×	0.2×	0.3×
2025	0.3×	0.1×	0.5×
2024	7.8×	5.5×	54.6×
2023	30.7×	27.3×	59.7×
2022	28.1×	27.4×	55.7×
2021	42.5×	40.3×	164×
2020	42.1×	18.9×	62.7×
2019	32.0×	11.2×	36.5×
2018	16.0×	15.9×	42.6×
2017	36.5×	26.2×	99.5×
2016	49.0×	32.2×	115×

Against its peers

Companies in Drug Manufacturers - General nearest Citius Pharmaceuticals' size, closest first, today.

Company	Price to book ratio
CTXRCitius Pharmaceuticals	0.2×
ATNMActinium Pharmaceuticals	1.6×
SPROSpero Therapeutics	1.5×
LFVNLifevantage	2.2×
Peer median	1.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Citius Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.